Interestingly, a clinical phase I study is currently ongoing for children and adult AML patients for treatment with CD33-CLEC12A CAR T-cells followed by allo-SCT (ClinicalTrials.gov Identifier: NCT03795779). Here, CD33 is linked to acute myeloid leukemia.